Article
Oncology
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Sang Cheul Oh, Young Soo Park, Taeil Son, Mi Ran Jung, Mi Hwa Heo, Hark Kyun Kim, ChoHyun Park, Chang Hak Yoo, Jin-Hyuk Choi, Dae Young Zang, You Jin Jang, Ji Young Sul, Jong Gwang Kim, Beom Su Kim, Seung-Hoon Beom, Sang Hee Cho, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyun Ki Kim, Moon-Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh
Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Hironori Ishigami, Yasushi Tsuji, Hisashi Shinohara, Yasuhiro Kodera, Mitsuro Kanda, Hiroshi Yabusaki, Seiji Ito, Motohiro Imano, Hiroharu Yamashita, Akio Hidemura, Hironori Yamaguchi, Takeo Fukagawa, Koji Oba, Joji Kitayama, Yasuyuki Seto
Summary: This randomized, phase III study aims to verify the efficacy of intraperitoneal paclitaxel (PTX) in preventing peritoneal recurrence in gastric cancer patients. Patients will receive different chemotherapy regimens and the effectiveness of the treatment will be evaluated through follow-up results.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Koki Kawakami, Yohei Sasaki, Satoshi Takao, Natsuko Takao, Ryoji Hyakudomi, Tetsu Yamamoto, Yoshitsugu Tajima
Summary: This study aimed to evaluate the feasibility of adjuvant chemotherapy with S-1 in patients after esophagectomy. The results showed that S-1 could be safely and continuously administered as adjuvant chemotherapy for patients with esophageal cancer regardless of neoadjuvant chemotherapy (NAC).
Article
Oncology
Akiko Serizawa, Hidekazu Kuramochi, Kiyoaki Taniguchi, Masaho Ota, Satoshi Katagiri, Takuji Yamada, Sho Kotake, Shunichi Ito, Kazuomi Suzuki, Masakazu Yamamoto
Summary: The study demonstrated that neoadjuvant S-1 and oxaliplatin is highly effective for advanced gastric cancer, achieving an acceptable R0 resection rate with relatively few severe toxicities and good compliance.
Article
Oncology
Fang Yang, Zhiqiang Yan, Wei Nie, Zeying Liu, Xingzhen Cheng, Wei Wang, Chunyan Shao, Gui Fu, Yanni Yu
Summary: This study investigated the correlation between the expression of LACTB and LC3 and the clinical outcomes of patients with advanced gastric cancer treated with oxaliplatin plus S-1 neoadjuvant chemotherapy. The results showed a significant negative correlation between the expression of LACTB and LC3 following NACT, with high LC3 expression and low LACTB expression associated with a poor response to treatment. The study suggests that LACTB and LC3 expression may serve as potential biomarkers for predicting the prognosis of patients with advanced gastric cancer receiving NACT.
Review
Oncology
Juan Sun, Xianze Wang, Zimu Zhang, Ziyang Zeng, Siwen Ouyang, Weiming Kang
Summary: Research on predicting the sensitivity of NACT for gastric cancer spans multiple aspects including biomarkers, inflammatory indicators, and imaging assessments. While numerous studies have been conducted on biomarkers, a unified conclusion has not yet been reached. Inflammatory indicators have been shown to be associated with the survival and prognosis of patients undergoing NACT, and imaging assessments such as CT, MRI, and PET may offer unique advantages in early screening for NACT-sensitive patients through careful integration and optimization.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Alina Desiree Sando, Reidun Fougner, Elin Synnove Royset, Hong Yan Dai, Jon Erik Gronbech, Erling Audun Bringeland
Summary: Evaluation of response following neoadjuvant chemotherapy (NAC) in gastric cancer has been widely debated. The aim of this study was to investigate downsizing and downstaging as methods of response evaluation. The findings suggest that comparing the baseline radiological CT stage to the pathological stage following NAC is a useful method for stratifying patients based on their long-term survival rates.
Article
Oncology
Kohei Kasahara, Chikara Kunisaki, Sho Sato, Hiroki Kondo, Masazumi Takahashi, Yuko Tamura, Nobuhiro Tsuchiya, Yusaku Tanaka, Kei Sato, Jun Kimura, Takashi Kosaka, Hidetaka Ono, Hirochika Makino, Hirotoshi Akiyama, Itaru Endo
Summary: This study aimed to evaluate the long-term outcomes of neoadjuvant chemotherapy using the DCS regimen in stage III gastric cancer patients. The results showed that the 5-year RFS and OS rates were 69.8% and 74.3%, respectively. Immune-nutritional status before and after NAC significantly affected the long-term survival of patients.
ANTICANCER RESEARCH
(2023)
Review
Oncology
Jiuzhou Chen, Yaru Guo, Miao Fang, Yan Yuan, Youqi Zhu, Yong Xin, Longzhen Zhang
Summary: This study evaluated the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy for resectable gastric cancer. The results showed that neoadjuvant chemoradiotherapy had better efficacy, improved survival rates, and fewer adverse effects compared to neoadjuvant chemotherapy. Therefore, neoadjuvant chemoradiotherapy has great potential as an effective therapy for resectable gastric cancers.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Tetsu Yamamoto, Ryoji Hyakudomi, Kiyoe Takai, Kazunari Ishitobi, Yuki Uchida, Yoshitsugu Tajima
Summary: The study evaluated the feasibility, safety, and efficacy of postoperative adjuvant chemotherapy with docetaxel/cisplatin/S-1 (DCS) in patients with stage III gastric cancer after curative gastrectomy. Results showed that DCS regimen was acceptable with significant efficacy, indicating it as an effective postoperative treatment option for stage III gastric cancer patients.
Article
Oncology
Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Hitoshi Katai, Takaki Yoshikawa, Seiji Ito, Masahide Kaji, Yutaka Kimura, Motohiro Hirao, Makoto Yamada, Akira Kurita, Masakazu Takagi, Sang-Woong Lee, Akinori Takagane, Hiroshi Yabusaki, Jun Hihara, Narikazu Boku, Takeshi Sano, Mitsuru Sasako
Summary: For scirrhous-type gastric cancer, neoadjuvant chemotherapy with S-1 plus cisplatin did not demonstrate a survival benefit, with D2 surgery followed by adjuvant chemotherapy remaining the standard treatment.
Article
Oncology
Chenghai Zhang, Binghong Wu, Hong Yang, Zhendan Yao, Nan Zhang, Fei Tan, Maoxing Liu, Kai Xu, Lei Chen, Jiadi Xing, Ming Cui, Xiangqian Su
Summary: This study compared the efficacy of neoadjuvant chemotherapy with oxaliplatin plus S-1 (SOX) regimen and paclitaxel plus S-1 (PTXS) regimen in locally advanced gastric cancer patients. The results showed no significant differences between the two regimens in terms of treatment response, postoperative complications, and overall survival.
Article
Oncology
Lin Jiang, Zhiqiang Ma, Xin Ye, Weiming Kang, Jianchun Yu
Summary: In a retrospective study on gastric cancer patients, factors such as age <60, histological type of poor differentiation or signet-ring cell carcinoma, and weight loss during neoadjuvant chemotherapy were identified as independent risk factors for the effect of neoadjuvant chemotherapy. Patients with weight loss >2.95% during neoadjuvant chemotherapy may have a worse chemotherapy effect. Providing timely nutritional support such as oral nutritional supplements to maintain patients' body weight is crucial for improving the effect of neoadjuvant chemotherapy.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Xin Zhang, Hejing Huang, Dejun Yang, Peng Wang, Xin Huang, Zunqi Hu, Yu Zhang, Ronglin Yan, Zhenxin Zhu, Qingping Cai
Summary: For patients with gastric cancer and peritoneal metastasis, neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) shows better survival rates and surgical resection rates compared to neoadjuvant systemic chemotherapy (NSC).
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Biochemistry & Molecular Biology
Xuejun Gan, Shen Li, Yiding Wang, Hong Du, Ying Hu, Xiaofang Xing, Xiaojing Cheng, Yan Yan, Ziyu Li
Summary: The expression of ASPH was found to be higher in gastric cancer patients undergoing neoadjuvant chemotherapy (NACT), and was associated with prognosis. In vitro and in vivo experiments showed that ASPH knockout enhanced the inhibitory effects of chemotherapeutic drugs on cell proliferation, migration, and invasion. Therefore, ASPH may serve as a candidate biomarker to predict prognosis and a novel therapeutic target for gastric cancer patients treated with NACT.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)